AU2006277836B8 - 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation - Google Patents

3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation Download PDF

Info

Publication number
AU2006277836B8
AU2006277836B8 AU2006277836A AU2006277836A AU2006277836B8 AU 2006277836 B8 AU2006277836 B8 AU 2006277836B8 AU 2006277836 A AU2006277836 A AU 2006277836A AU 2006277836 A AU2006277836 A AU 2006277836A AU 2006277836 B8 AU2006277836 B8 AU 2006277836B8
Authority
AU
Australia
Prior art keywords
dihydrotetrabenazine
isomer
cis
pct
isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2006277836A
Other languages
English (en)
Other versions
AU2006277836A1 (en
AU2006277836B2 (en
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Laboratories International Bermuda SRL
Original Assignee
Biovail Laboratories International Barbados SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Laboratories International Barbados SRL filed Critical Biovail Laboratories International Barbados SRL
Publication of AU2006277836A1 publication Critical patent/AU2006277836A1/en
Assigned to BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL reassignment BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL Request for Assignment Assignors: CAMBRIDGE LABORATORIES (IRELAND) LIMITED
Publication of AU2006277836B2 publication Critical patent/AU2006277836B2/en
Application granted granted Critical
Publication of AU2006277836B8 publication Critical patent/AU2006277836B8/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2006277836A 2005-08-05 2006-08-04 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation Expired - Fee Related AU2006277836B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516168.2 2005-08-05
GBGB0516168.2A GB0516168D0 (en) 2005-08-05 2005-08-05 Pharmaceutical compounds
PCT/GB2006/002909 WO2007017643A1 (en) 2005-08-05 2006-08-04 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION

Publications (3)

Publication Number Publication Date
AU2006277836A1 AU2006277836A1 (en) 2007-02-15
AU2006277836B2 AU2006277836B2 (en) 2011-11-10
AU2006277836B8 true AU2006277836B8 (en) 2011-12-08

Family

ID=34984180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006277836A Expired - Fee Related AU2006277836B8 (en) 2005-08-05 2006-08-04 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation

Country Status (23)

Country Link
US (1) US20090275605A1 (OSRAM)
EP (2) EP1964565A1 (OSRAM)
JP (1) JP2009503045A (OSRAM)
KR (1) KR20080033501A (OSRAM)
CN (1) CN101321528B (OSRAM)
AT (1) ATE412414T1 (OSRAM)
AU (1) AU2006277836B8 (OSRAM)
CA (1) CA2620952A1 (OSRAM)
CY (1) CY1108729T1 (OSRAM)
DE (1) DE602006003415D1 (OSRAM)
DK (1) DK1861100T3 (OSRAM)
ES (1) ES2317564T3 (OSRAM)
GB (1) GB0516168D0 (OSRAM)
HR (1) HRP20090017T3 (OSRAM)
MX (1) MX2008001546A (OSRAM)
NZ (1) NZ566010A (OSRAM)
PL (1) PL1861100T3 (OSRAM)
PT (1) PT1861100E (OSRAM)
RS (1) RS50720B (OSRAM)
RU (1) RU2409364C2 (OSRAM)
SI (1) SI1861100T1 (OSRAM)
WO (1) WO2007017643A1 (OSRAM)
ZA (2) ZA200801170B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
GB0721669D0 (en) * 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
MX2016009817A (es) 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
US10550120B2 (en) 2016-03-25 2020-02-04 Tohoku University Indole alkaloid compound having immune checkpoint inhibitory action
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005213525A1 (en) * 2004-02-11 2005-08-25 Biovail Laboratories International (Barbados) Srl Dihydrotetrabenazines and pharmaceutical compositions containing them

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132147A (en) * 1964-05-05
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US2843591A (en) 1958-07-15 Method for preparing same
US3009918A (en) * 1961-11-21 Chz ch
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3123609A (en) * 1964-03-03 Benzo
US3159638A (en) * 1964-12-01 Xcha-chj
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
US3634431A (en) * 1969-12-22 1972-01-11 Miles Lab Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2178965B (en) * 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
EP2529730A1 (en) * 2003-06-16 2012-12-05 ANDRX Pharmaceuticals LLC. Oral sustained-release composition
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005213525A1 (en) * 2004-02-11 2005-08-25 Biovail Laboratories International (Barbados) Srl Dihydrotetrabenazines and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
RS50720B (sr) 2010-08-31
PL1861100T3 (pl) 2009-06-30
EP1964565A1 (en) 2008-09-03
CY1108729T1 (el) 2014-04-09
ZA200801171B (en) 2009-08-26
WO2007017643A1 (en) 2007-02-15
ES2317564T3 (es) 2009-04-16
MX2008001546A (es) 2008-04-04
ATE412414T1 (de) 2008-11-15
CA2620952A1 (en) 2007-02-15
DK1861100T3 (da) 2008-12-15
US20090275605A1 (en) 2009-11-05
HK1111084A1 (en) 2008-08-01
CN101321528A (zh) 2008-12-10
RU2008108516A (ru) 2009-09-10
NZ566010A (en) 2010-05-28
SI1861100T1 (sl) 2009-04-30
GB0516168D0 (en) 2005-09-14
DE602006003415D1 (de) 2008-12-11
RU2409364C2 (ru) 2011-01-20
AU2006277836A1 (en) 2007-02-15
CN101321528B (zh) 2011-05-25
EP1861100B1 (en) 2008-10-29
JP2009503045A (ja) 2009-01-29
AU2006277836B2 (en) 2011-11-10
KR20080033501A (ko) 2008-04-16
PT1861100E (pt) 2008-12-26
ZA200801170B (en) 2009-12-30
EP1861100A1 (en) 2007-12-05
HRP20090017T3 (hr) 2009-03-31

Similar Documents

Publication Publication Date Title
AU2006277836B8 (en) 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
JP6920295B2 (ja) テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
EP1855677B1 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
EP1885363B1 (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
TW202304928A (zh) 抗癌核荷爾蒙受體標靶化合物
US20110039877A1 (en) Use of 3, 11b-cis-dihydrotetrabenazine in the treatment of multiple sclerosis and autoimmune myelitis
WO2008013966A2 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
TW202012384A (zh) 特定芳基普拉二烯內酯化合物及其使用方法
JP2025527175A (ja) ウロリチン誘導体の治療的使用
HK1121405A (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
HK1111084B (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
HK1125575A (en) 3,11b cis dihydrotetrabanezine for the treatment of psychoses
HK1111083B (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
CN101351205A (zh) 治疗精神分裂症及其它精神病的3,11b-顺式-二氢丁苯那嗪
HK1121972A (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington's disease

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL

Free format text: FORMER APPLICANT(S): CAMBRIDGE LABORATORIES (IRELAND) LIMITED

TH Corrigenda

Free format text: IN VOL 25, NO 44, PAGE(S) 5594 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL, APPLICATION NO. 2006277836, UNDER INID (72) CORRECT THE CO -INVENTOR TO YARROW, JEAN ELISABETH

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee